AlloVir Inc logo


AlloVir Inc


Earnings Summary

Net Profits


Net Profits:

AlloVir Inc’s net profit fell -18.76% since last year same period to $-44.64Mn in the Q2 2022. On a quarterly growth basis, AlloVir Inc has generated -1.77% fall in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the AlloVir Inc post its latest quarter earnings

EPS Estimate Current Quarter
EPS Estimate Current Year


EPS Estimate Current Quarter:

AlloVir Inc’s earning per share (EPS) estimates for the current quarter stand at -0.73 - a 8.75% jump from last quarter’s estimates.

EPS Estimate Current Year:

AlloVir Inc’s earning per share (EPS) estimates for the current year stand at -0.73.

Key Ratios

Key ratios of the AlloVir Inc post its Q2 2022 earnings

Return on Assets (ROA)
Return on Equity (ROE)
Dividend Per Share (DPS)


Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. AlloVir Inc’s return on assets (ROA) stands at -0.45.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. AlloVir Inc’s return on equity (ROE) stands at -0.83.

Dividend Per Share (DPS):

AlloVir Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %

Company Information

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.

AlloVir Inc
Health Technology